Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study Assessing the Efficacy and Safety of an Anti-TNF-OX40L NANOBODY Molecule, SAR442970, in Participants With Moderate to Severe Hidradenitis Suppurativa

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study Assessing the Efficacy and Safety of an Anti-TNF-OX40L NANOBODY Molecule, SAR442970, in Participants With Moderate to Severe Hidradenitis Suppurativa

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brivekimig (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Proof of concept; Therapeutic Use
  • Acronyms HS OBTAIN
  • Sponsors Sanofi

Most Recent Events

  • 23 Jan 2025 Status changed from active, no longer recruiting to completed.
  • 25 Jul 2024 According to a Sanofi media release, results expected in H1 2025.
  • 05 Jun 2024 Planned End Date changed from 7 Feb 2025 to 8 Jan 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top